Business Context and Reporting Period
Prothena Corporation plc is an Ireland-incorporated, late-stage clinical biotechnology company focused on protein dysregulation and investigational therapies for neurodegenerative and rare amyloid diseases. Its pipeline includes wholly owned programs such as birtamimab, PRX012 and PRX123, and partnered programs with Roche and Bristol Myers Squibb (BMS). The company also remains eligible for potential milestone payments from Novo Nordisk.
This unaudited Form 10-Q covers the three and nine months ended September 30, 2023, with comparisons to the corresponding 2022 periods. Prothena had 53.7 million ordinary shares outstanding as of October 26, 2023.
Financial Performance and Liquidity
| Metric | Q3 2023 | Q3 2022 | 9M 2023 | 9M 2022 |
|---|---|---|---|---|
| Total revenue | $84.9 million | $1.5 million | $91.1 million | $4.0 million |
| Research and development expense | $57.9 million | $39.9 million | $158.7 million | $98.7 million |
| General and administrative expense | $16.6 million | $12.0 million | $44.9 million | $36.8 million |
| Income (loss) from operations | $10.3 million | $(50.3) million | $(112.5) million | $(131.5) million |
| Net income (loss) | $21.9 million | $(45.8) million | $(79.6) million | $(123.3) million |
| Net income (loss) per diluted share | $0.38 | $(0.97) | $(1.50) | $(2.63) |
Q3 operating margin was approximately 12.1% and net margin was approximately 25.8%, compared with negative margins in Q3 2022. For the nine-month period, operating margin was approximately negative 123.6% and net margin was approximately negative 87.4%.
- Q3 and nine-month collaboration revenue was $84.9 million and $91.0 million, respectively, almost entirely from BMS. The nine-month total also included $50,000 of license and intellectual property revenue.
- Q3 revenue included $72.9 million related to the BMS tau global license, comprising the $55.0 million global option exercise fee and $17.9 million of previously deferred revenue, plus $4.7 million under a supply agreement and additional tau development-services revenue.
- Interest income increased to $8.5 million in Q3 and $22.9 million for nine months, driven by higher interest rates and cash balances.
- Cash, cash equivalents and restricted cash totaled $673.1 million at September 30, 2023, including $670.9 million of cash and cash equivalents. Cash and cash equivalents declined from $710.4 million at December 31, 2022.
- Net cash used in operating activities was $82.9 million for the first nine months, versus $103.8 million in the prior-year period. Net cash used in investing activities was $1.3 million, while financing activities provided $44.6 million.
- Working capital was $637.2 million at September 30, 2023, compared with $669.0 million at year-end 2022.
- The filing does not report conventional interest-bearing debt. Liabilities primarily comprised deferred revenue, accounts payable, accrued research and development costs, and operating lease liabilities.
Material Changes Versus the Prior Comparable Period
- Revenue increased by 5,494% in Q3 and 2,187% for nine months, primarily because BMS exercised global rights for the tau program in July 2023.
- R&D expense increased 45% in Q3 and 61% for nine months, mainly due to higher clinical-trial spending for PRX012 and birtamimab, higher personnel and consulting costs, and related share-based compensation.
- G&A expense increased 39% in Q3 and 22% for nine months, primarily due to higher personnel-related costs.
- The company reported Q3 net income, but remained unprofitable for the first nine months and had an accumulated deficit of $912.6 million.
- Shareholders’ equity declined modestly to $617.2 million from $622.0 million at December 31, 2022, despite approximately $44.6 million of financing cash inflows, reflecting the nine-month net loss and other equity activity.
- Prothena commenced its Brisbane, California facility lease in July 2023, recording an approximately $11.4 million right-of-use asset and a $3.6 million lease liability. The lease requires approximately $14.9 million of payments through September 2028.
Guidance, Outlook, Commentary and Risks
- Management expects full-year 2023 net cash used in operating and investing activities of approximately $148 million to $161 million.
- Management expects full-year 2023 R&D and G&A expenses to increase versus 2022, primarily because of clinical-trial activity, personnel costs and share-based compensation.
- Management believes cash and cash equivalents at September 30, 2023 are sufficient to fund obligations for at least the next twelve months, but expects to require additional capital to continue development and potential commercialization activities. Future financing could include equity, debt, collaboration payments or other arrangements and may dilute shareholders.
- Topline data from the Phase 3 AFFIRM-AL trial of birtamimab and Roche’s Phase 2b PADOVA trial of prasinezumab were expected in 2024. Initial topline data from PRX012 Phase 1 trials were expected by year-end 2023, and an IND for PRX123 was expected by year-end 2023.
- BMS reported that Phase 1 data supported moving BMS-986446 into a Phase 2 trial in the first half of 2024. BMS will report future program updates.
- Prothena remains dependent on Roche, BMS and Novo Nordisk for development and potential milestone or royalty payments. Potential future payments are contingent on clinical, regulatory and commercial achievements and are not assured.
- Key risks include clinical-trial failure or delay, regulatory non-approval, dependence on third-party collaborators and manufacturers, intellectual-property challenges, inability to obtain additional capital, share dilution, foreign-exchange exposure, cybersecurity and data privacy risks, and changing healthcare reimbursement requirements.
- The company reported no material legal proceedings, no off-balance-sheet arrangements and no defaults upon senior securities. Management concluded that disclosure controls were effective as of September 30, 2023.
Most Important Facts for Investors to Verify
- Whether AFFIRM-AL, PADOVA, PRX012 and other clinical programs meet stated enrollment, data and timing expectations.
- The sustainability of revenue, given that 2023 revenue was heavily concentrated in a one-time BMS global license transaction rather than product sales.
- The timing and probability of additional BMS, Roche and Novo Nordisk milestones, royalties and other collaboration payments.
- Actual cash burn relative to the $148 million to $161 million full-year 2023 forecast and the resulting timing of any future financing.
- The impact of rising R&D spending, share-based compensation and potential equity issuance on dilution and long-term profitability.
- Deferred revenue of $67.7 million at September 30, 2023, including $67.4 million classified as non-current, and the timing of its recognition.
- Lease, supplier and license commitments totaling approximately $31.5 million, excluding future clinical-development and personnel spending.